Feb 24, 2026 07:30PM
Dec 2, 2025 04:00AM
Oct 19, 2025 09:00PM
Aug 19, 2025 12:42AM
Jul 27, 2025 10:31PM
May 20, 2025 08:00AM
Mar 21, 2025 05:54AM Antengene Announces 2024 Full-Year Financial Results, Proprietary Programs Advancing to Pivotal Trials with Accelerating Multi-market Revenue Ramp Up
Jan 21, 2025 10:01PM
Sep 16, 2024 06:00AM
Sep 8, 2024 08:30PM
Aug 23, 2024 12:28AM
Aug 5, 2024 08:00AM
Mar 22, 2024 06:00AM
Mar 20, 2024 08:30AM Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia
Mar 20, 2024 08:30AM
Oct 31, 2023 08:30PM
Aug 25, 2023 07:35AM
May 23, 2023 05:16AM
May 17, 2023 02:47PM
Oct 31, 2022 08:21AM
Sep 18, 2022 09:23PM Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA
May 22, 2022 10:00PM
May 18, 2022 02:50AM
May 15, 2022 10:47PM
May 13, 2022 06:00AM
May 12, 2022 08:30PM
Apr 6, 2022 07:36AM
Mar 29, 2022 09:00PM Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes
Mar 18, 2022 10:08AM
Mar 9, 2022 05:55AM
Mar 1, 2022 07:35PM
Dec 29, 2021 08:42PM
Dec 19, 2021 09:56PM
Dec 17, 2021 09:24AM
Dec 14, 2021 05:00AM Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting
Nov 18, 2021 11:51PM
Nov 18, 2021 07:30PM
Nov 14, 2021 07:23PM
Nov 9, 2021 03:25AM
Nov 1, 2021 08:30PM
Oct 31, 2021 08:30PM
Aug 23, 2021 08:30PM Antengene Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China
Jul 25, 2021 08:38PM
Jul 13, 2021 09:35PM
Jul 5, 2021 08:00PM
Jun 18, 2021 01:51AM
Jun 3, 2021 08:00PM
May 12, 2021 08:00PM
May 5, 2021 11:13PM Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines
Apr 28, 2021 08:23PM

324,764 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All